Literature DB >> 21106270

Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.

Sandra Beinhardt, Susanne Rasoul-Rockenschaub, Thomas Matthias Scherzer, Peter Ferenci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21106270     DOI： 10.1016/j.jhep.2010.09.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  15 in total

1.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

2.  Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Authors:  Jeremie Guedj; Harel Dahari; Ralf T Pohl; Peter Ferenci; Alan S Perelson
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

3.  Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism.

Authors:  Janela McClure; Daciana H Margineantu; Ian R Sweet; Stephen J Polyak
Journal:  Virology       Date:  2013-11-27       Impact factor: 3.616

Review 4.  Silymarin for HCV infection.

Authors:  Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Antivir Ther       Date:  2012-09-25

5.  Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.

Authors:  Noémie Calland; Marie-Emmanuelle Sahuc; Sandrine Belouzard; Véronique Pène; Pierre Bonnafous; Ahmed Atef Mesalam; Gaspard Deloison; Véronique Descamps; Sevser Sahpaz; Czeslaw Wychowski; Olivier Lambert; Priscille Brodin; Gilles Duverlie; Philip Meuleman; Arielle R Rosenberg; Jean Dubuisson; Yves Rouillé; Karin Séron
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

6.  Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.

Authors:  Katharina Esser-Nobis; Inés Romero-Brey; Tom M Ganten; Jérôme Gouttenoire; Christian Harak; Rahel Klein; Peter Schemmer; Marco Binder; Paul Schnitzler; Darius Moradpour; Ralf Bartenschlager; Stephen J Polyak; Wolfgang Stremmel; François Penin; Christoph Eisenbach; Volker Lohmann
Journal:  Hepatology       Date:  2013-02-07       Impact factor: 17.425

Review 7.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

8.  Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway.

Authors:  C H Lin; C H Li; P L Liao; L S Tse; W K Huang; H W Cheng; Y W Cheng
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Authors:  Laetitia Canini; Swati DebRoy; Zoe Mariño; Jessica M Conway; Gonzalo Crespo; Miquel Navasa; Massimo D'Amato; Peter Ferenci; Scott J Cotler; Xavier Forns; Alan S Perelson; Harel Dahari
Journal:  Antivir Ther       Date:  2014-06-10

Review 10.  Hepatitis C virus and natural compounds: a new antiviral approach?

Authors:  Noémie Calland; Jean Dubuisson; Yves Rouillé; Karin Séron
Journal:  Viruses       Date:  2012-10-17       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.